BackFirst Tracks Biotherapeutics Ordinary Shares When-Issued Overview

First Tracks Biotherapeutics Ordinary Shares When-Issued Total Assets

Track First Tracks Biotherapeutics Ordinary Shares When-Issued's total assets ($180M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$183.14M

Peer trimmed avg / median

Loading

First Tracks Biotherapeutics Ordinary Shares When-Issued Total Assets History

Loading

First Tracks Biotherapeutics Ordinary Shares When-Issued vs. peers: Total Assets Comparison

Loading

First Tracks Biotherapeutics Ordinary Shares When-Issued Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

First Tracks Biotherapeutics Ordinary Shares When-Issued (TRAXV) FAQ

First Tracks Biotherapeutics Ordinary Shares When-Issued's total assets stands at $180M as of June 2026. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether First Tracks Biotherapeutics Ordinary Shares When-Issued's total assets is expanding or contracting. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how First Tracks Biotherapeutics Ordinary Shares When-Issued's total assets evolved across reporting periods, while the comparison chart places TRAXV next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total assets is commonly used to spot outliers. First Tracks Biotherapeutics Ordinary Shares When-Issued's reading of $180M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.